The game behind the "outperforming the market" rating for Microsoft Corporation (MSFT.US): strong momentum in cloud and AI, but the market is starting to discount the risk of "disruptive" factors.
Microsoft (MSFT.US) is listed by analysts as one of the best technology stocks worth holding long term. Recently, Mizuho Securities and Citigroup lowered their target prices but maintained their "outperform the market" and "buy" ratings.
Microsoft Corporation (MSFT.US) is considered one of the best long-term tech stocks by analysts. Recently, Mizuho Securities lowered its target price for Microsoft Corporation stock from $640 to $620, but maintained an "outperform" rating. Citigroup also lowered its target price, but still maintained a "buy" rating.
It is worth noting that this adjustment was made by Mizuho as part of their preview of the fourth quarter performance for large software stocks in the 2025 fiscal year. Analysts at the firm pointed out that channel research remains strong overall, public cloud data remains steady, and the adoption of Artificial Intelligence (AI) is very strong.
Despite the positive fundamentals, the firm added that investor concerns about the disruptive impact of AI are increasing and starting to affect the valuation multiples of software companies. Mizuho stated that the industry is experiencing multiple valuation compressions, which is the main reason for their target price downgrade.
On the other hand, Citigroup also lowered its target price for Microsoft Corporation from $690 to $660 on January 21, while maintaining a "buy" rating.
Citigroup analysts said that their distributor surveys and partner checks show a more complex market environment ahead of Microsoft Corporation's second quarter performance release in the 2026 fiscal year. The firm expects the performance of Azure cloud services in the second quarter to exceed expectations, but due to a forecasted weakness in the personal computer (PC) market, performance estimates for Microsoft Corporation's non-Azure businesses have been lowered.
Related Articles

New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?
New Stock Preview | From "Deep Squatting" in Performance to Global Leapfrogging: Decoding the Breakthrough Logic of Sirio Pharma (300791.SZ)

From the sharp decline in the entrance to the "doji star", is the reversal of the low-stage consolidation of INNOGEN-B (02591) imminent?

New stock preview | Hujia Technology: Dual pressure of single brand and online dependence Can high-tech profit margins continue?

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


